Navigation Links
BioLife Solutions Announces Record Quarterly Revenue
Date:4/6/2011

BOTHELL, Wash., April 6, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011. This represents 6% sequential growth over the fourth quarter of 2010 and 19 percent growth from the first quarter of 2010.  

(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Mike Rice, Chairman and CEO, commented on the Company's revenue by stating, "We're pleased with the progress we made last year and in the first quarter of 2011 in generating revenue growth to reduce our operating loss as we strive to reach profitability.  First quarter revenue was a mix of orders shipped to new accounts, including a new contract manufacturing customer, and strong orders from our numerous existing customers in the developing regenerative medicine market, where our proprietary biopreservation media products are used to extend stability and increase viability of biologics used in cell therapy and tissue-engineering applications.  We also realized strong growth in our indirect distribution channel, with year-to-date revenue already more than 50% of our full year 2010 total.  Our partners continue to build awareness of the value of our best-in-class biopreservation media products, and their efforts are resulting in increasing orders from their end customers."

MedMarket Diligence, LLC, estimates that the current worldwide market for regenerative medicine products and services is growing at 20 percent annually.  Rice commented, "We expect pre-formulated biopreservation media products such as our HypoThermosol® and CryoStor® to continue to displace 'home-brew' cocktails, creating demand for clinical grade preservation reagents that will grow at greater than the overall end market rate.  We estimate that in-house formulated 'home-brew' storage and freeze media comprise 80% of the market." 

The Company's financial statements for the first quarter of 2011 will be included in the Company's 10-Q quarterly report, which it expects to file with the U.S. Securities and Exchange Commission on or before May 16, 2011.

About BioLife Solutions, Inc.:Founded in 1998, with the initial development of its intellectual property base in 1992, BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation (freeze) media products for cells, tissues, and organs, and also performs contract media manufacturing and contract research and development. The Company's proprietary HypoThermosol and CryoStor platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death.  US FDA Master Files are available for cross-reference. BioLife's enabling technology provides research and clinical customers significantly extended storage stability and improved post-preservation viability and recovery of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com.

Safe Harbor StatementThis shareholder communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about BioLife Solutions, Inc. (the "Company") and its future operating results, strategies, and product development plans. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties.  Actual results could differ materially from the results expressed or implied in these forward-looking statements.  Factors that may cause or contribute to such differences are more fully discussed, as are other factors, in Part I, Item1A. "Risk Factors" of the Company's Form 10-K for the fiscal year ended December 31, 2010, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as may be legally necessary, even if the Company's estimates should change.Media Relations:Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300

(949) 474-4300len@allencaron.com

matt@allencaron.com
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry
2. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
5. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
6. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
7. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
8. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
9. Elektas New Line of Stereotactic Treatment Solutions is Redefining Excellence in Stereotaxy, a Case at a Time
10. Aon eSolutions Launches Clinical Trials Module
11. MedNet Solutions to Sponsor and Exhibit at the 2008 Advanced Medical Technology Association Conference in Washington, D.C.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):